
Cahill Represents Initial Purchasers in \$1 Billion Notes Offering by Valeant Pharmaceuticals

Date: 01/30/15

Cahill represented Barclays Capital as lead book-running manager and the co-managers in connection with the Rule 144A offering of \$1,000,000,000 aggregate principal amount of 5.5% Senior Notes due 2023 by Valeant Pharmaceuticals International, Inc. Proceeds from the offering will be used to refinance existing indebtedness and for general corporate purposes.

Attorneys

- William M. Hartnett
- Timothy B. Howell
- Noah B. Newitz
- Mark Loftus
- Patrick Gordon